Health
SURMOUNT
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that around two thirds of participants of the SURMOUNT-1 trial had only regained 5% or less of their so-called nadir (or lowest weight) three years after beginning treatment with tirzepatide. The study is by Professor Louis […]
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that around two thirds of participants of the SURMOUNT-1 trial had only regained 5% or less of their so-called nadir (or lowest weight) three years after beginning treatment with tirzepatide. The study is by Professor Louis Aronne, Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York, NY, USA, and co-authors from Eli Lilly and Company, Indianapolis, IN, USA, which funded the study.
Obesity management is a long-term journey during which fluctuations in body weight are expected to occur. For some patients, a previous nadir (or lowest) weight can become a point of focus (and disappointment when it cannot be reached again). However, there is not yet clear literature that nadir weight is clinically relevant. This post hoc analysis of the SURMOUNT-1 study, at 3 years, aimed to assess weight regain from nadir weight over 3 years (36 months / 176 weeks) with tirzepatide treatment.
The original SURMOUNT-1 trial was published in NEJM in 2022, and found that, across 72 weeks, participants with obesity treated with 5 mg, 10 mg, or 15 mg of tirzepatide once weekly experienced substantial and sustained reductions in body weight.
This analysis included 690 tirzepatide-adherent participants (65% female, 35% male) with a mean age of 49 years, a mean weight of 107 kg, and a mean BMI of 38.6 kg/m2 who were chosen from the original SURMOUNT-1 cohort on the basis they had been treatment-adherent across the 3-years (with 75% or more of planned doses received) and were living with obesity(a BMI of at least 30 kg/m²), or overweight (a BMI of at least 27 kg/m²) and prediabetes, and had been participants in the SURMOUNT-1 study and had lost at least 5% of their baseline weight when reaching their nadir weight (the lowest weight achieved during treatment).
Weight regain from nadir to Week 176 was defined as the difference between percent weight reduction from baseline to nadir and percent weight reduction from baseline to Week 176. Weight regain analyses were calculated as a mean across groups and were categorised as less than 5%, 5% to 10%, and 10% or more weight regain.
The analysis showed that the mean time to nadir weight was 22 months (96 weeks). The mean percent weight reduction at nadir weight was 23.1%. The mean percent weight regain from nadir weight to Week 176 was 3.7%, meaning that across the 690 participants over these three years there was a mean percent weight reduction of 19.4% (23.1% minus 3.7%).
At Week 176, 73%, 19%, and 8% of participants treated with tirzepatide 5 mg (227 participants) regained less than 5%, 5% to 10%, and 10% or more from nadir weight, respectively. Similarly, 65%, 26%, and 9% of participants treated with tirzepatide 10 mg (N=239) regained less than 5%, 5% to 10%, and 10% or more weight from nadir to week 176, respectively. Among participants treated with tirzepatide 15 mg (N=224), 73%, 20%, and 7% experienced less than 5%, 5% to 10%, and 10% or more weight regain from nadir to Week 176, respectively.
The authors have not yet analysed if there are any differences in weight gain between men and women or between older and younger participants.
This analysis found that 70% of participants treated with tirzepatide had limited weight regain – meaning 5% or less – after their nadir, or lowest weight. Less than 10% of participants regained 10% or more from their nadir weight. Overall, these findings suggest that most participants receiving tirzepatide had a relatively stable weight journey over 3 years in the SURMOUNT-1 3-year study, and managed to avoid any substantial weight regain.”
Dr. Louis Aronne, Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine
European Association for the Study of Obesity
Health
Why Personal Growth Drives Business Success
About Icebug Icebug is a Swedish footwear brand on a mission to empower people to get outside — regardless of the season. Founded in 2001, the company is best known for its innovative traction technologies, making it a go-to for runners, hikers, and outdoor lovers facing slippery or challenging terrain. As the first outdoor footwear […]
About Icebug
Icebug is a Swedish footwear brand on a mission to empower people to get outside — regardless of the season. Founded in 2001, the company is best known for its innovative traction technologies, making it a go-to for runners, hikers, and outdoor lovers facing slippery or challenging terrain. As the first outdoor footwear brand to become climate positive, Icebug leads with bold sustainability actions, transparency, and a commitment to doing business differently. Headquartered in Jonsered, just outside Gothenburg, Icebug combines nature-first values with cutting-edge design and a deep respect for the planet.
CEO David Ekelund believes this connection to nature is essential for both mental health and in-novative thinking. With mandatory “Wellness Hours” three times a week, all employees spend at least an hour outside — whether walking, running, or simply breathing fresh forest air. It’s part of a bigger shift: a commitment to inner development and new ways of working in a changing world. As Ekelund shares on a walk through the forests of Västra Götaland, breaking with business-as-usual has helped Icebug thrive — from the inside out.
It’s quite difficult to isolate where mental issues are coming from. Is it really because of work? Or can it be a parent who is ill or a child having problems at school? But it’s for sure, that you’re not one person at work and then you’re another person in your private life. We are basically one person.
The underlying assumption is, that people get more dusk worn down at work. They need the weekend or a vacation to rest. I think it’s not a really good way of having it. What if instead, we can make the workplace the place where actual health and well-being are increased? Where people can develop towards their full potential.
We know that physical activity also gives mental well-being, but that’s only one part of it. About 3 years ago, we decided that we wanted to work on inner development. This was really a departure from business as usual.
The core idea of business as usual being professional at work. But we all have strong sides and weak sides. And if we go to work, spending a lot of time trying to hide our weak side and always show our strong side, our “better side”, we lose a lot of opportunities to learn. Instead spending a lot of energy doing that, we could use it to develop together.
